ClinicalTrials.gg

TargetBeta

ERBB2

erb-b2 receptor tyrosine kinase 2 · also NEU, HER-2, CD340, HER2 · CD molecules

37 programs in company-led studies act on ERBB2, from 28 companies: 22 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (21 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
trastuzumab deruxtecanruleDaiichi Sankyophase 44931 running–NCIt
tucatinibrulePfizerphase 42511 running–ChEMBL
pertuzumabruleHoffmann-La Rochephase 4567 running–NCIt
TrastuzumabruleHoffmann-La Rochephase 4855 running–NCIt
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 33632 running–NCIt
disitamab vedotinRemeGenphase 33628 running–the company's pipeline
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 32121 running–the company's pipeline
Lutetium-177Novartisphase 32420 runningFAPthe company's pipeline
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 31312 running–the company's pipeline
Gallium-68Philogenphase 3179 runningFAPthe company's pipeline
zongertinibruleBoehringer Ingelheimphase 3157 running–NCIt
anbenitamabCSPC Pharmaceutical Groupphase 3127 running–a judged reading
anbenitamab repodatecanCSPC Pharmaceutical Groupphase 387 running–a judged reading
sunvozertinibruleDizal Pharmaceuticalsphase 3125 runningEGFRNCIt
zanidatamabruleJazz Pharmaceuticalsphase 3115 running–NCIt
dulpatatugFosun Pharmaphase 365 running–a judged reading
trastuzumab pamirtecanruleDualityBiophase 355 running–NCIt
Anti-HER2 Bispecific Antibody TQB2930Sino Biopharmaceuticalphase 354 running–the company's pipeline
trastuzumab envedotinCSPC Pharmaceutical Groupphase 373 running–a judged reading
Anti-HER2 Antibody-drug Conjugate IBI354ruleInnovent Biologicsphase 333 running–NCIt
sevabertinibruleBayerphase 382 runningEGFRNCIt
bizrolertinibHoffmann-La Rochephase 352 running–a judged reading
trastuzumab botidotinruleSichuan Kelun Pharmaceuticalphase 342 running–NCIt
Anti-HER2/Topoisomerase I Inhibitor ADC GQ1005ruleGeneQuantum Healthcare (Suzhou)phase 322 running–NCIt
HLX87Fosun Pharmaphase 322 running–the company's pipeline
Anti-HER2 Monoclonal Antibody QL1209ruleQilu Pharmaceuticalphase 321 running–NCIt
HRS-4508Jiangsu HengRui Medicinephase 255 running–the company's pipeline
Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705rule3SBiophase 243 runningPDCD1NCIt
enozertinibruleORIC Pharmaceuticalsphase 232 runningEGFRNCIt
anvatabart opadotinJohnson & Johnsonphase 241 running–a judged reading
Anti-HER2 Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A251ruleHUTCHMEDphase 211 running–NCIt
Anti-HER2/Topoisomerase I Inhibitor/ATR Inhibitor Antibody-drug Conjugate CLIO-8221ruleCallio Therapeuticsphase 211 running–NCIt
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleBlossomHill Therapeuticsphase 211 runningEGFRNCIt
kg of tqb2102 for injectionSino Biopharmaceuticalphase 211 running–the company's pipeline
Antibody-drug Conjugate BL-M17D1Sichuan Biokin Pharmaceuticalphase 132 running–the company's pipeline
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 111 runningEGFRthe studies' text
HER2 Mutant-selective Inhibitor CGT4255ruleCogent Biosciencesphase 111 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.